Alnylam Pharmaceuticals Inc. (ALNY) PT Raised to $89.00
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had its price objective increased by stock analysts at Chardan Capital from $73.00 to $89.00 in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s price target indicates a potential upside of 114.10% from the company’s current price.
The analysts wrote, “We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space.””
Several other analysts also recently issued reports on the company. JPMorgan Chase & Co. downgraded Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $83.00 to $51.00 in a research note on Thursday, October 6th. Jefferies Group decreased their price target on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating for the company in a research note on Thursday, October 6th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $106.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, October 24th. Credit Suisse Group AG set a $145.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 30th. Finally, Leerink Swann restated a “market perform” rating and set a $43.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 10th. Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $68.38.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 0.22% during midday trading on Wednesday, hitting $41.66. The stock had a trading volume of 1,353,698 shares. The firm’s market cap is $3.57 billion. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $109.10. The firm has a 50-day moving average of $40.00 and a 200 day moving average of $59.82.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by $0.07. The company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $9.14 million. Alnylam Pharmaceuticals had a negative return on equity of 33.97% and a negative net margin of 1,041.16%. The business’s revenue was up 116.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.91) EPS. On average, analysts expect that Alnylam Pharmaceuticals will post ($4.80) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Alnylam Pharmaceuticals Inc. (ALNY) PT Raised to $89.00” was first posted by Financial Market News and is the sole property of of Financial Market News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be read at http://www.financial-market-news.com/alnylam-pharmaceuticals-inc-alny-given-new-89-00-price-target-at-chardan-capital/1210245/.
In other news, CMO Akshay Vaishnaw sold 29,165 shares of the stock in a transaction that occurred on Wednesday, November 30th. The stock was sold at an average price of $44.99, for a total value of $1,312,133.35. Following the completion of the transaction, the chief marketing officer now directly owns 34,915 shares of the company’s stock, valued at approximately $1,570,825.85. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David E. I. Pyott bought 27,900 shares of the company’s stock in a transaction dated Thursday, October 13th. The stock was bought at an average cost of $37.00 per share, with a total value of $1,032,300.00. The disclosure for this purchase can be found here. 4.00% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the company. Mn Services Vermogensbeheer B.V. boosted its position in shares of Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 87 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $128,000. Janney Montgomery Scott LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $223,000. Seven Eight Capital LLC boosted its position in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $199,000. 89.81% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.